Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEVILLA_A: ivonescimab versus FOLFOX in second-line advanced biliary tract cancer
2024-515875-36-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Mar 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivonescimab, fluorouracil, oxaliplatin and folinic acid in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by Unicancer. Primary endpoint: Progression-free survival. Planned start Mar 2025; status: authorised.
02
Drugs
ivonescimabfluorouraciloxaliplatinfolinic acid
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2024-515875-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515875-36-00.